购物车
- 全部删除
- 您的购物车当前为空
BPTU (BMS-646786) 是一种非核苷酸类P2Y1受体变构拮抗剂,能够阻断位于胃肠道神经肌肉接头的 P2Y1受体,具有抗血栓活性。
为众多的药物研发团队赋能,
让新药发现更简单!
BPTU (BMS-646786) 是一种非核苷酸类P2Y1受体变构拮抗剂,能够阻断位于胃肠道神经肌肉接头的 P2Y1受体,具有抗血栓活性。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 273 | 现货 | |
2 mg | ¥ 386 | 现货 | |
5 mg | ¥ 663 | 现货 | |
10 mg | ¥ 997 | 现货 | |
25 mg | ¥ 2,320 | 现货 | |
50 mg | ¥ 3,490 | 现货 | |
100 mg | ¥ 4,960 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 697 | 现货 |
产品描述 | BPTU (BMS-646786) is an allosteric antagonist of P2Y1 (EC50 = 0.06-0.3 μM). Non-nucleotide ligand. Binds receptor outside of the helical bundle. Blocks inhibition of spontaneous contraction of rat and mouse colon induced by electrical field stimulation, nicotine and P2Y agonists. Antithrombotic; reduces platelet aggregation. |
靶点活性 | P2Y1:0.06-0.3 μM(EC50) |
体内活性 | Octreotide处理组与生理盐水组相比显著降低了肿瘤体积。Octreotide-PPSG (1.4 mg/kg, i.p.) 的抗肿瘤效果比Octreotide-soln (100 μg/kg, i.p.) 更为显著。Octreotide治疗显著抑制了携带原发性HCC的大鼠SSTR2和SSTR5的表达水平。相较于Octreotide-soln处理组,Octreotide-PPSG对SSTR2和SSTR5表达的抑制作用更强。 Octreotide Acetate 盐的测试剂量在2小时内显著降低血清胃泌素水平至基线的约三分之一,且效果持续约6小时。在第21天,开始使用持续释放配方的 Octreotide Acetate 盐(5 mg肌肉注射, 每4周一次)进行治疗。 |
别名 | BMS-646786 |
分子量 | 445.43 |
分子式 | C23H22F3N3O3 |
CAS No. | 870544-59-5 |
Smiles | CC(C)(C)c1ccccc1Oc1ncccc1NC(=O)Nc1ccc(OC(F)(F)F)cc1 |
密度 | 1.307 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
溶解度信息 | DMSO: 20 mg/mL (44.9 mM), Sonication is recommended. | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容